Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Scientists at the Mainz University Medical Center gain new insights into Taspase1 function

Exploiting "molecular glues" to target disease relevant proteolytic enzymes

Scientists at the University Medical Center of Johannes Gutenberg University Mainz in Germany identified a novel strategy to target the oncologically relevant protein-cleaving enzyme Taspase1. Taspase1 levels are not only elevated in cancer cells of patients with head and neck tumors and other solid malignancies but the enzyme is also critical for the development of leukemias.

Central to this concept is the approach to inhibit the enzyme’s activity by 'gluing together' individual Taspase1 molecules. The results of a study undertaken by Professor Dr. Roland Stauber of the ENT Department at the Mainz University Medical Center were recently published in The FASEB Journal.

Protein-cleaving enzymes, so-called proteases, are not only significantly involved in physiological processes in the healthy body, such as blood clotting, but also play critical roles in illnesses, such as cancer, Alzheimer's, and infectious diseases. Several protease inhibitors have already been developed and are being used against some of these 'disease-causing' enzymes with varying success in the clinics. However, one representative of this protein family in particular – the protease Taspase1 – is troubling researchers worldwide." We currently do not have any drug that can inhibit Taspase1. And we still do not understand in sufficient detail how this enzyme really works," says Stauber.

Almost ten years ago, the team found enhanced levels of Taspase1 in the cancer cells of patients with head and neck tumors. At that time, the function of the protease in tumor cells and its relevance for disease was still unknown. Recent findings support the oncological importance of Taspase1 for solid malignancies and leukemias. Taspase1 appears to override control mechanisms in healthy cells by cleaving various other proteins, thereby significantly promoting cancer development. As a result of extensive research supported by funding provided by the Head and Neck Tumor Research Foundation [Stiftung Tumorforschung], the German Cancer Aid, the Thyssen Foundation, and Johannes Gutenberg University Mainz, the researchers have now gained new insights into the enzyme’s molecular functions. "Previously, it was assumed that two Taspase1 enzymes had to come together in order to be active and cleave other cellular proteins," explains Stauber. "Our latest results not only demonstrate that one Taspase1 molecule is sufficient for this, but also that we can even block the tumor-promoting properties of the enzyme by 'gluing' two Taspase1 molecules together."

Hence, the Mainz-based researchers identified a completely novel approach to developing drugs that may be used to inhibit Taspase1. "We are now searching for chemical substances that could function as molecular Taspase1 'adhesives'," adds Stauber. As part of the so-called Chemical BioMedicine Initiative, the scientists are betting on nature's vast chemical repertoire. "Natural products from fungi and marine sponges are a highly privileged source for potential new drugs. Evolution already pre-checked the biological qualities of such chemical substances in living organisms. Thus, we have a good chance of finding the right chemical decoys," predicts Stauber. "The robotic platform at the Mainz Screening Center combined with our Taspase1 assays will play a leading role in this search for the 'needle in the haystack'."

C. Bier et. al., Allosteric inhibition of Taspase1's pathobiological activity by enforced dimerization in vivo, The FASEB Journal, 26:8, 23 May 2012,


Petra Giegerich | idw
Further information:

More articles from Life Sciences:

nachricht ‘Farming’ bacteria to boost growth in the oceans
24.10.2016 | Max-Planck-Institut für marine Mikrobiologie

nachricht Calcium Induces Chronic Lung Infections
24.10.2016 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Oasis of life in the ice-covered central Arctic

24.10.2016 | Earth Sciences

‘Farming’ bacteria to boost growth in the oceans

24.10.2016 | Life Sciences

Light-driven atomic rotations excite magnetic waves

24.10.2016 | Physics and Astronomy

More VideoLinks >>>